Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC.

Leidy D Caraballo Galva Xiaotao Jiang Mohamed S HusseinHuajun ZhangRui MaoPierce BrodyYibing PengAiwu Ruth HeMercy Kehinde-IgeRamses SadekXiangguo QiuHuidong Shi Yukai He

Published in: Hepatology (Baltimore, Md.) (2021)

The low-avidity 8F8-BBz CART resists exhaustion and apoptosis inside tumor lesions, demonstrating a greater therapeutic potential than high-avidity CARTs.

Keyphrases

oxidative stress
cell death
cell cycle arrest
signaling pathway